Dear Colleagues,

Hepatocellular cancer arises on background of liver cirrhosis for the vast majority of patients. Often, the presentation is with liver failure when palliation of symptoms may be the only option. Although prognosis for this cancer remains poor, with incidence and mortality rates being virtually the same, there has been tremendous progress over the last two decades in terms of services and therapy options.

The proportion of patients being diagnosed with earlier stages of cancer has improved due to the growth in screening programmes for patients with cirrhosis, or otherwise, at high risk of developing hepatocellular cancer. A range of therapy options, from transplantation, surgery, ablation, stereotactic body radiotherapy to transarterial chemoembolisation and selective internal radiotherapy to many forms of systemic chemotherapy, are now available.

Physicians are also improving services for maintaining liver function and dealing with features of liver failure through effective treatments for causes of liver damage, good nutritional support and clinical nurse management of ascites, and encephalopathy, among other approaches.

This issue describes the current state of affairs and likely future developments concerning the management of hepatocellular cancer.

Dr. Tahir Shah
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• liver function
• hepatocellular cancer
• liver function
• liver nutrition
• ascites
• encephalopathy